Q03347 (RUNX1_MOUSE) Reviewed, UniProtKB/Swiss-Prot
Last modified
May 1, 2013.
Version 135.
History...
Names·Attributes·General annotation·Ontologies·Interactions·Alt products·Sequence annotation·Sequences·References·Cross-refs·Entry info·DocumentsCustomize order
Names·Attributes·General annotation·Ontologies·Interactions·Alt products·Sequence annotation·Sequences·References·Cross-refs·Entry info·DocumentsCustomize orderNames and origin
| Protein names | Recommended name: Runt-related transcription factor 1 Alternative name(s): Acute myeloid leukemia 1 protein Core-binding factor subunit alpha-2 Short name=CBF-alpha-2 Oncogene AML-1 Polyomavirus enhancer-binding protein 2 alpha B subunit Short name=PEA2-alpha B Short name=PEBP2-alpha B SL3-3 enhancer factor 1 alpha B subunit SL3/AKV core-binding factor alpha B subunit | ||||
| Gene names |
| ||||
| Organism | Mus musculus (Mouse) [Reference proteome] | ||||
| Taxonomic identifier | 10090 [NCBI] | ||||
| Taxonomic lineage | Eukaryota › Metazoa › Chordata › Craniata › Vertebrata › Euteleostomi › Mammalia › Eutheria › Euarchontoglires › Glires › Rodentia › Sciurognathi › Muroidea › Muridae › Murinae › Mus › Mus![]() |
Protein attributes
| Sequence length | 451 AA. |
| Sequence status | Complete. |
| Protein existence | Evidence at protein level |
General annotation (Comments)
| Function | CBF binds to the core site, 5'-PYGPYGGT-3', of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, LCK, IL-3 and GM-CSF promoters. Essential for the development of normal hematopoiesis. Isoform 4 shows higher binding activities for target genes and binds TCR-beta-E2 and RAG-1 target site with threefold higher affinity than other isoforms. It is less effective in the context of neutrophil terminal differentiation. Acts synergistically with ELF4 to transactivate the IL-3 promoter and with ELF2 to transactivate the BLK promoter. Inhibits KAT6B-dependent transcriptional activation By similarity. Ref.7 Ref.9 |
| Subunit structure | Heterodimer with CBFB. RUNX1 binds DNA as a monomer and through the Runt domain. DNA-binding is increased by heterodimerization. Interacts with TLE1 and ALYREF/THOC4. Interacts with HIPK2, ELF1, ELF2 and SPI1. Interacts via its Runt domain with the ELF4 N-terminal region. Interaction with ELF2 isoform 2 (NERF-1a) may act to repress RUNX1-mediated transactivation. Interacts with KAT6A and KAT6B. Interacts with SUV39H1, leading to abrogation of transactivating and DNA-binding properties of RUNX1 By similarity. Interacts with YAP1. Interaction with CDK6 prevents myeloid differentiation, reducing its transcription transactivation activity By similarity. Found in a complex with PRMT5, RUNX1 and CBFB. Ref.8 Ref.10 |
| Subcellular location | |
| Tissue specificity | Isoform 4 is expressed at high levels in thymus, spleen and T-cell lines and at lower levels in myeloid cell lines and nonhematopoietic cells. Isoform 5 is expressed ubiquitously in lumbar vertebrae, brain, kidney, heart, muscle, ovary and osteoblast-like cell line MC3T3-E1. |
| Developmental stage | Differentially expressed during hematopoietic differentiation. Isoform AML1-B is readily detectable in undifferentiated embryonic stem (es) cells and peak expression is seen on day 6 of differentiation, followed by a gradual decline thereafter. Isoform AML1-C is undetectable in undifferentiated es cells, but is gradually up-regulated along with differentiation and reaches its highest levels on day 8 and this expression is maintained through day 12. Isoform 5 is expressed at high levels at 6-8 dpc and then levels decrease on 12 dpc. Isoform 4 expression is high throughout T-cell development, declines with natural killer cell maturation, and appears to be transiently reduced and then restored during B-cell development. |
| Domain | A proline/serine/threonine rich region at the C-terminus is necessary for transcriptional activation of target genes. |
| Post-translational modification | Phosphorylated in its C-terminus upon IL-6 treatment. Phosphorylation enhances interaction with KAT6A By similarity. Ref.10 Methylated By similarity. Phosphorylated in Ser-249 Thr-273 and Ser-276 by HIPK2 when associated with CBFB and DNA. This phosphorylation promotes subsequent EP300 phosphorylation. Ref.10 |
| Involvement in disease | Mice with an Runx1 lacking the DNA-binding region are found to die between embryonic days 11.5 to 12.5 due to hemorrhaging in the central nervous system. This hemorrhaging is preceded by necrosis and hematopoiesis is blocked. |
| Sequence similarities | Contains 1 Runt domain. |
Ontologies
Binary interactions
With | Entry | #Exp. | IntAct | Notes |
|---|---|---|---|---|
| Tbx21 | Q9JKD8 | 3 | EBI-3863873,EBI-3863870 |
Alternative products
| This entry describes 5 isoforms produced by alternative splicing. [Align] [Select] | ||||||
| Isoform 1 (identifier: Q03347-1) Also known as: AML1-B; PEB2-alpha B1; This isoform has been chosen as the 'canonical' sequence. All positional information in this entry refers to it. This is also the sequence that appears in the downloadable versions of the entry. | ||||||
| Isoform 2 (identifier: Q03347-2) Also known as: PEB2-alpha B2; The sequence of this isoform differs from the canonical sequence as follows: 178-178: R → N 179-242: Missing. | ||||||
| Isoform 3 (identifier: Q03347-3) The sequence of this isoform differs from the canonical sequence as follows: 92-182: VALGDVPDGT...PREPRRHRQK → LLPEEGGGRS...ASEVSKREFF 183-451: Missing. | ||||||
| Isoform 4 (identifier: Q03347-4) Also known as: AML1-C; The sequence of this isoform differs from the canonical sequence as follows: 1-5: MRIPV → MASDSIFESFPSYPQCFMR | ||||||
| Isoform 5 (identifier: Q03347-5) The sequence of this isoform differs from the canonical sequence as follows: 242-303: DARQIQPSPP...LSTAPDLTAF → KNPTEPTTLC...EYLYSEKCGC 304-451: Missing. |
Sequence annotation (Features)
| Feature key | Position(s) | Length | Description | Graphical view | Feature identifier | ||||||||||||||||||||||||||||||||||
Molecule processing | |||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chain | 1 – 451 | 451 | Runt-related transcription factor 1 | PRO_0000174656 | |||||||||||||||||||||||||||||||||||
Regions | |||||||||||||||||||||||||||||||||||||||
| Domain | 50 – 178 | 129 | Runt | ||||||||||||||||||||||||||||||||||||
| Region | 80 – 84 | 5 | Interaction with DNA By similarity | ||||||||||||||||||||||||||||||||||||
| Region | 135 – 143 | 9 | Interaction with DNA By similarity | ||||||||||||||||||||||||||||||||||||
| Region | 168 – 177 | 10 | Interaction with DNA By similarity | ||||||||||||||||||||||||||||||||||||
| Region | 291 – 370 | 80 | Interaction with KAT6A By similarity | ||||||||||||||||||||||||||||||||||||
| Region | 307 – 399 | 93 | Interaction with KAT6B By similarity | ||||||||||||||||||||||||||||||||||||
| Compositional bias | 187 – 451 | 265 | Pro/Ser/Thr-rich | ||||||||||||||||||||||||||||||||||||
Sites | |||||||||||||||||||||||||||||||||||||||
| Binding site | 112 | 1 | Chloride 1 By similarity | ||||||||||||||||||||||||||||||||||||
| Binding site | 116 | 1 | Chloride 1; via amide nitrogen By similarity | ||||||||||||||||||||||||||||||||||||
| Binding site | 139 | 1 | Chloride 2 By similarity | ||||||||||||||||||||||||||||||||||||
| Binding site | 170 | 1 | Chloride 2; via amide nitrogen By similarity | ||||||||||||||||||||||||||||||||||||
Amino acid modifications | |||||||||||||||||||||||||||||||||||||||
| Modified residue | 14 | 1 | Phosphothreonine By similarity | ||||||||||||||||||||||||||||||||||||
| Modified residue | 21 | 1 | Phosphoserine By similarity | ||||||||||||||||||||||||||||||||||||
| Modified residue | 24 | 1 | N6-acetyllysine By similarity | ||||||||||||||||||||||||||||||||||||
| Modified residue | 43 | 1 | N6-acetyllysine By similarity | ||||||||||||||||||||||||||||||||||||
| Modified residue | 249 | 1 | Phosphoserine; by HIPK2 Ref.10 | ||||||||||||||||||||||||||||||||||||
| Modified residue | 266 | 1 | Phosphoserine By similarity | ||||||||||||||||||||||||||||||||||||
| Modified residue | 268 | 1 | Phosphoserine By similarity | ||||||||||||||||||||||||||||||||||||
| Modified residue | 273 | 1 | Phosphothreonine; by HIPK2 By similarity | ||||||||||||||||||||||||||||||||||||
| Modified residue | 276 | 1 | Phosphoserine; by HIPK2 Ref.10 | ||||||||||||||||||||||||||||||||||||
Natural variations | |||||||||||||||||||||||||||||||||||||||
| Alternative sequence | 1 – 5 | 5 | MRIPV → MASDSIFESFPSYPQCFMR in isoform 4. | VSP_005930 | |||||||||||||||||||||||||||||||||||
| Alternative sequence | 92 – 182 | 91 | VALGD…RHRQK → LLPEEGGGRSRWRSADGQSE PRGQRLRRLLKGAACSRSLW SFSLSLGWGGDAALPWRPSG GSASEVSKREFF in isoform 3. | VSP_005931 | |||||||||||||||||||||||||||||||||||
| Alternative sequence | 178 | 1 | R → N in isoform 2. | VSP_005932 | |||||||||||||||||||||||||||||||||||
| Alternative sequence | 179 – 242 | 64 | Missing in isoform 2. | VSP_005933 | |||||||||||||||||||||||||||||||||||
| Alternative sequence | 183 – 451 | 269 | Missing in isoform 3. | VSP_005934 | |||||||||||||||||||||||||||||||||||
| Alternative sequence | 242 – 303 | 62 | DARQI…DLTAF → KNPTEPTTLCLCWSPRRRKH RGCQAFLGALRELLKPRSIS WEPNEENAVPSAEYLYSEKC GC in isoform 5. | VSP_005935 | |||||||||||||||||||||||||||||||||||
| Alternative sequence | 304 – 451 | 148 | Missing in isoform 5. | VSP_005936 | |||||||||||||||||||||||||||||||||||
Experimental info | |||||||||||||||||||||||||||||||||||||||
| Mutagenesis | 80 | 1 | R → A: Interferes with DNA-binding. Ref.12 | ||||||||||||||||||||||||||||||||||||
| Mutagenesis | 109 | 1 | N → A: Interferes with heterodimerization. Ref.12 | ||||||||||||||||||||||||||||||||||||
| Mutagenesis | 113 | 1 | Y → A: Interferes with heterodimerization. Ref.12 | ||||||||||||||||||||||||||||||||||||
| Mutagenesis | 142 | 1 | R → A: Interferes with DNA-binding. Ref.12 | ||||||||||||||||||||||||||||||||||||
| Mutagenesis | 144 | 1 | K → M: Interferes with DNA-binding. Ref.12 | ||||||||||||||||||||||||||||||||||||
| Mutagenesis | 149 | 1 | T → A: Interferes with heterodimerization. Ref.12 | ||||||||||||||||||||||||||||||||||||
| Mutagenesis | 170 | 1 | V → A: No effect. Ref.12 | ||||||||||||||||||||||||||||||||||||
| Mutagenesis | 171 | 1 | D → A: Interferes with DNA-binding. Ref.12 | ||||||||||||||||||||||||||||||||||||
| Mutagenesis | 174 | 1 | R → A: Interferes with DNA-binding. Ref.12 | ||||||||||||||||||||||||||||||||||||
| Mutagenesis | 177 | 1 | R → A: Interferes with DNA-binding. Ref.12 | ||||||||||||||||||||||||||||||||||||
| Mutagenesis | 249 | 1 | S → A: Reduced phosphorylation. Ref.10 | ||||||||||||||||||||||||||||||||||||
| Mutagenesis | 276 | 1 | S → A: Reduced phosphorylation. Ref.10 | ||||||||||||||||||||||||||||||||||||
| Sequence conflict | 37 – 38 | 2 | GP → A in CAA65976. Ref.3 | ||||||||||||||||||||||||||||||||||||
Secondary structure | |||||||||||||||||||||||||||||||||||||||
Helix Strand Turn | |||||||||||||||||||||||||||||||||||||||
| Helix | 51 – 57 | 7 | |||||||||||||||||||||||||||||||||||||
| Turn | 59 – 61 | 3 | |||||||||||||||||||||||||||||||||||||
| Beta strand | 63 – 67 | 5 | |||||||||||||||||||||||||||||||||||||
| Beta strand | 70 – 72 | 3 | |||||||||||||||||||||||||||||||||||||
| Beta strand | 77 – 80 | 4 | |||||||||||||||||||||||||||||||||||||
| Beta strand | 90 – 95 | 6 | |||||||||||||||||||||||||||||||||||||
| Beta strand | 102 – 109 | 8 | |||||||||||||||||||||||||||||||||||||
| Beta strand | 112 – 115 | 4 | |||||||||||||||||||||||||||||||||||||
| Beta strand | 117 – 119 | 3 | |||||||||||||||||||||||||||||||||||||
| Beta strand | 121 – 125 | 5 | |||||||||||||||||||||||||||||||||||||
| Beta strand | 128 – 130 | 3 | |||||||||||||||||||||||||||||||||||||
| Beta strand | 146 – 152 | 7 | |||||||||||||||||||||||||||||||||||||
| Beta strand | 154 – 156 | 3 | |||||||||||||||||||||||||||||||||||||
| Beta strand | 158 – 161 | 4 | |||||||||||||||||||||||||||||||||||||
| Beta strand | 166 – 171 | 6 | |||||||||||||||||||||||||||||||||||||
Sequences
| ||||||||||||||||||||||||||||||||||||||||||
References
| [1] | "Isolation of PEBP2 alpha B cDNA representing the mouse homolog of human acute myeloid leukemia gene, AML1." Bae S.-C., Yamaguchi-Iwai Y., Ogawa E., Maruyama M., Inuzuka M., Kagoshima H., Shigesada K., Satake M., Ito Y. Oncogene 8:809-814(1993) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). Tissue: Fibroblast. |
| [2] | "PEBP2 alpha B/mouse AML1 consists of multiple isoforms that possess differential transactivation potentials." Bae S.-C., Ogawa E., Maruyama M., Oka H., Satake M., Shigesada K., Jenkins N.A., Gilbert D.J., Copeland N.G., Ito Y. Mol. Cell. Biol. 14:3242-3252(1994) [PubMed] [Europe PMC] [Abstract] Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2). Tissue: Fibroblast. |
| [3] | Calabi F. Submitted (APR-1996) to the EMBL/GenBank/DDBJ databases Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3). Strain: BALB/c. Tissue: Thymus. |
| [4] | "Identification and expression of a novel 3'-exon of mouse Runx1/Pebp2alphaB/Cbfa2/AML1 gene." Tsuji K., Noda M. Biochem. Biophys. Res. Commun. 274:171-176(2000) [PubMed] [Europe PMC] [Abstract] Cited for: PARTIAL NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5). |
| [5] | "Identification of an alternatively spliced form of the mouse AML1/RUNX1 gene transcript AML1c and its expression in early hematopoietic development." Fujita Y., Nishimura M., Taniwaki M., Abe T., Okuda T. Biochem. Biophys. Res. Commun. 281:1248-1255(2001) [PubMed] [Europe PMC] [Abstract] Cited for: PARTIAL NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4). Strain: 129/Ola. Tissue: Embryo. |
| [6] | "Expression and function of a stem cell promoter for the murine CBFalpha2 gene: distinct roles and regulation in natural killer and T cell development." Telfer J.C., Rothenberg E.V. Dev. Biol. 229:363-382(2001) [PubMed] [Europe PMC] [Abstract] Cited for: PARTIAL NUCLEOTIDE SEQUENCE [GENOMIC DNA], ALTERNATIVE SPLICING (ISOFORM 4). Strain: C57BL/6. Tissue: Thymus. |
| [7] | "AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis." Okuda T., van Deursen J., Hiebert S.W., Grosveld G., Downing J.R. Cell 84:321-330(1996) [PubMed] [Europe PMC] [Abstract] Cited for: FUNCTION IN LIVER HEMATOPOIESIS. |
| [8] | "The histone- and PRMT5-associated protein COPR5 is required for myogenic differentiation." Paul C., Sardet C., Fabbrizio E. Cell Death Differ. 19:900-908(2012) [PubMed] [Europe PMC] [Abstract] Cited for: IDENTIFICATION IN A COMPLEX WITH PRMT5; RUNX1 AND CBFB. |
| [9] | "Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis." Wang Q., Stacy T., Binder M., Marin-Padilla M., Sharpe A.H., Speck N.A. Proc. Natl. Acad. Sci. U.S.A. 93:3444-3449(1996) [PubMed] [Europe PMC] [Abstract] Cited for: FUNCTION IN NECROSIS AND HEMORRHAGING. |
| [10] | "Roles of HIPK1 and HIPK2 in AML1- and p300-dependent transcription, hematopoiesis and blood vessel formation." Aikawa Y., Nguyen L.A., Isono K., Takakura N., Tagata Y., Schmitz M.L., Koseki H., Kitabayashi I. EMBO J. 25:3955-3965(2006) [PubMed] [Europe PMC] [Abstract] Cited for: INTERACTION WITH HIPK2, PHOSPHORYLATION AT SER-249 AND SER-276 BY HIPK2, MUTAGENESIS OF SER-249 AND SER-276. |
| [11] | "Crystallization and preliminary X-ray analyses of quaternary, ternary and binary protein-DNA complexes with involvement of AML1/Runx-1/CBFalpha Runt domain, CBFbeta and the C/EBPbeta bZip region." Tahirov T.H., Inoue-Bungo T., Sasaki M., Shiina M., Kimura K., Sato K., Kumasaka T., Yamamoto M., Kamiya N., Ogata K. Acta Crystallogr. D 57:850-853(2001) [PubMed] [Europe PMC] [Abstract] Cited for: X-RAY CRYSTALLOGRAPHY (2.65 ANGSTROMS) OF 62-177 IN COMPLEX WITH CEBPB; CBFB AND DNA. |
| [12] | "Structural analyses of DNA recognition by the AML1/Runx-1 Runt domain and its allosteric control by CBFbeta." Tahirov T.H., Inoue-Bungo T., Morii H., Fujikawa A., Sasaki M., Kimura K., Shiina M., Sato K., Kumasaka T., Yamamoto M., Ishii S., Ogata K. Cell 104:755-767(2001) [PubMed] [Europe PMC] [Abstract] Cited for: X-RAY CRYSTALLOGRAPHY (2.65 ANGSTROMS) OF 60-182 IN COMPLEX WITH CEBPB; CBFB AND DNA, MUTAGENESIS OF ARG-80; ASN-109; TYR-113; ARG-142; LYS-144; THR-149; VAL-170; ASP-171; ARG-174 AND ARG-177. |
| [13] | "The RUNX1 Runt domain at 1.25A resolution: a structural switch and specifically bound chloride ions modulate DNA binding." Baeckstroem S., Wolf-Watz M., Grundstroem C., Haerd T., Grundstroem T., Sauer U.H. J. Mol. Biol. 322:259-272(2002) [PubMed] [Europe PMC] [Abstract] Cited for: X-RAY CRYSTALLOGRAPHY (1.25 ANGSTROMS) OF 60-173. |
| + | Additional computationally mapped references. |
Cross-references
Sequence databases | |||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EMBL GenBank DDBJ | D26532 mRNA. Translation: BAA05535.1. D13802 mRNA. Translation: BAA02960.1. X97306 mRNA. Translation: CAA65976.1. AB046930 mRNA. Translation: BAB08105.1. AF345649 mRNA. Translation: AAK29784.1. AF193030 Genomic DNA. Translation: AAG32957.1. | ||||||||||||||||||||||||||||||||||||||||||||||||
| IPI | IPI00131214. IPI00230038. IPI00230039. IPI00230040. IPI00230041. | ||||||||||||||||||||||||||||||||||||||||||||||||
| PIR | A56017. | ||||||||||||||||||||||||||||||||||||||||||||||||
| RefSeq | NP_033951.2. NM_009821.2. | ||||||||||||||||||||||||||||||||||||||||||||||||
| UniGene | Mm.4081. Mm.470227. | ||||||||||||||||||||||||||||||||||||||||||||||||
3D structure databases | |||||||||||||||||||||||||||||||||||||||||||||||||
| PDBe RCSB PDB PDBj |
| ||||||||||||||||||||||||||||||||||||||||||||||||
| ProteinModelPortal | Q03347. | ||||||||||||||||||||||||||||||||||||||||||||||||
| SMR | Q03347. Positions 60-173, 319-345. | ||||||||||||||||||||||||||||||||||||||||||||||||
| ModBase | Search... | ||||||||||||||||||||||||||||||||||||||||||||||||
Protein-protein interaction databases | |||||||||||||||||||||||||||||||||||||||||||||||||
| DIP | DIP-40723N. | ||||||||||||||||||||||||||||||||||||||||||||||||
| IntAct | Q03347. 2 interactions. | ||||||||||||||||||||||||||||||||||||||||||||||||
| MINT | MINT-91306. | ||||||||||||||||||||||||||||||||||||||||||||||||
PTM databases | |||||||||||||||||||||||||||||||||||||||||||||||||
| PhosphoSite | Q03347. | ||||||||||||||||||||||||||||||||||||||||||||||||
Proteomic databases | |||||||||||||||||||||||||||||||||||||||||||||||||
| PaxDb | Q03347. | ||||||||||||||||||||||||||||||||||||||||||||||||
| PRIDE | Q03347. | ||||||||||||||||||||||||||||||||||||||||||||||||
Protocols and materials databases | |||||||||||||||||||||||||||||||||||||||||||||||||
| StructuralBiologyKnowledgebase | Search... | ||||||||||||||||||||||||||||||||||||||||||||||||
Genome annotation databases | |||||||||||||||||||||||||||||||||||||||||||||||||
| GeneID | 12394. | ||||||||||||||||||||||||||||||||||||||||||||||||
| KEGG | mmu:12394. | ||||||||||||||||||||||||||||||||||||||||||||||||
| UCSC | uc007zzk.2. mouse. | ||||||||||||||||||||||||||||||||||||||||||||||||
Organism-specific databases | |||||||||||||||||||||||||||||||||||||||||||||||||
| CTD | 861. | ||||||||||||||||||||||||||||||||||||||||||||||||
| MGI | MGI:99852. Runx1. | ||||||||||||||||||||||||||||||||||||||||||||||||
Phylogenomic databases | |||||||||||||||||||||||||||||||||||||||||||||||||
| eggNOG | NOG123889. | ||||||||||||||||||||||||||||||||||||||||||||||||
| HOGENOM | HOG000045616. | ||||||||||||||||||||||||||||||||||||||||||||||||
| HOVERGEN | HBG060268. | ||||||||||||||||||||||||||||||||||||||||||||||||
| InParanoid | Q03347. | ||||||||||||||||||||||||||||||||||||||||||||||||
| KO | K08367. | ||||||||||||||||||||||||||||||||||||||||||||||||
Gene expression databases | |||||||||||||||||||||||||||||||||||||||||||||||||
| CleanEx | MM_RUNX1. | ||||||||||||||||||||||||||||||||||||||||||||||||
| Genevestigator | Q03347. | ||||||||||||||||||||||||||||||||||||||||||||||||
| GermOnline | ENSMUSG00000022952. Mus musculus. | ||||||||||||||||||||||||||||||||||||||||||||||||
Family and domain databases | |||||||||||||||||||||||||||||||||||||||||||||||||
| Gene3D | 2.60.40.720. 1 hit. | ||||||||||||||||||||||||||||||||||||||||||||||||
| InterPro | IPR000040. AML1_Runt. IPR008967. p53-like_TF_DNA-bd. IPR012346. p53/RUNT-type_TF_DNA-bd. IPR013524. Runt_dom. IPR013711. RunxI_c_dom. IPR016554. TF_Runt-rel_RUNX. [Graphical view] | ||||||||||||||||||||||||||||||||||||||||||||||||
| PANTHER | PTHR11950. PTHR11950. 1 hit. | ||||||||||||||||||||||||||||||||||||||||||||||||
| Pfam | PF00853. Runt. 1 hit. PF08504. RunxI. 1 hit. [Graphical view] | ||||||||||||||||||||||||||||||||||||||||||||||||
| PIRSF | PIRSF009374. TF_Runt-rel_RUNX. 1 hit. | ||||||||||||||||||||||||||||||||||||||||||||||||
| PRINTS | PR00967. ONCOGENEAML1. | ||||||||||||||||||||||||||||||||||||||||||||||||
| SUPFAM | SSF49417. P53_like_DNA_bnd. 1 hit. | ||||||||||||||||||||||||||||||||||||||||||||||||
| PROSITE | PS51062. RUNT. 1 hit. [Graphical view] | ||||||||||||||||||||||||||||||||||||||||||||||||
| ProtoNet | Search... | ||||||||||||||||||||||||||||||||||||||||||||||||
Other | |||||||||||||||||||||||||||||||||||||||||||||||||
| EvolutionaryTrace | Q03347. | ||||||||||||||||||||||||||||||||||||||||||||||||
| NextBio | 281140. | ||||||||||||||||||||||||||||||||||||||||||||||||
| SOURCE | Search... | ||||||||||||||||||||||||||||||||||||||||||||||||
Entry information
| Entry name | RUNX1_MOUSE | ||||||||
| Accession | Primary (citable) accession number: Q03347 Secondary accession number(s): O08598 Q9ET65 | ||||||||
| Entry history |
| ||||||||
| Entry status | Reviewed (UniProtKB/Swiss-Prot) | ||||||||
| Annotation program | Chordata Protein Annotation Program | ||||||||
Relevant documents
| MGD cross-references Mouse Genome Database (MGD) cross-references in UniProtKB/Swiss-Prot |
| PDB cross-references Index of Protein Data Bank (PDB) cross-references |
| SIMILARITY comments Index of protein domains and families |

Clusters with
